UK markets closed

Aura Biosciences, Inc. (AURA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
7.31-0.23 (-3.05%)
At close: 04:00PM EDT
7.16 -0.15 (-2.05%)
After hours: 05:43PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 362.09M
Enterprise value 155.49M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.60
Enterprise value/revenue N/A
Enterprise value/EBITDA -5.68

Trading information

Stock price history

Beta (5Y monthly) 0.37
52-week change 3-31.87%
S&P500 52-week change 326.27%
52-week high 313.50
52-week low 35.99
50-day moving average 37.71
200-day moving average 38.68

Share statistics

Avg vol (3-month) 3179.71k
Avg vol (10-day) 391.25k
Shares outstanding 549.53M
Implied shares outstanding 649.53M
Float 831M
% held by insiders 17.51%
% held by institutions 176.18%
Shares short (30 Apr 2024) 42.76M
Short ratio (30 Apr 2024) 423.8
Short % of float (30 Apr 2024) 47.58%
Short % of shares outstanding (30 Apr 2024) 45.58%
Shares short (prior month 28 Mar 2024) 42.45M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-24.90%
Return on equity (ttm)-40.43%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -86.59M
Net income avi to common (ttm)-78.65M
Diluted EPS (ttm)-1.93
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)202.87M
Total cash per share (mrq)4.09
Total debt (mrq)19.32M
Total debt/equity (mrq)9.25%
Current ratio (mrq)21.97
Book value per share (mrq)4.22

Cash flow statement

Operating cash flow (ttm)-71.89M
Levered free cash flow (ttm)-46.54M